VenatoRx is a developing next-generation antibiotics to treat multi-drug resistant (MDR) infections.
Vividion is a biotechnology company focused on developing innovative therapeutics that treat major unmet clinical needs using the first platform for proteome-wide drug and target discovery.
Repare is developing new, precision oncology drugs for patients that target specific vulnerabilities of tumor cells.
Northern Biologics is developing novel therapeutic antibodies for the treatment of human diseases in oncology, fibrosis, and other diseases.
PIQUR is a Swiss pharmaceutical company focusing on the discovery and development of innovative small molecule therapeutics based on lipid kinase (PI3K) and mTOR inhibition for the treatment of cancer as well as other indications.
Anokion is focused on leveraging its proprietary immune tolerance technology to develop novel protein therapeutics and treatments for autoimmune diseases.
Mosaic Biomedicals is a Barcelona-based company that develops personalized cancer treatments with a dual mechanism of action to eliminate cancer stem cells and reactivate the tumor’s immune system. Mosaic’s innovative treatments are derived from a deep understanding of the tumor biology and aim to offer safer and more effective options to cancer patients.
AAVLife is a gene therapy company focused on developing treatments for rare diseases with great unmet medical need.
Inception IBD is focused on translating academic discoveries in the field of IBD into first-in-class small molecule drugs.
CRISPR Therapeutics is making use of significant advances in the field of gene editing and focused on translating the CRISPR-Cas9 technology in truly transformational therapeutics for common and rare genetic diseases.
Audentes is a biotechnology company committed to the development and commercialization of innovative new treatments for people with serious, rare diseases through the application of gene therapy technology.
GenSight is a leading company in gene therapy specialized in prevention of loss of vision and restoration of sight.
Inception 3 is focused on the discovery of therapeutics for sensorineural hearing loss. The company has entered into a partnership with Roche with a pre-negotiated acquisition at IND.
VLST Corp. has developed a novel and streamlined approach to speed the development of effective therapeutics for the treatment of inflammatory and autoimmune diseases.
Theraclone Sciences, Inc. is focused on developing novel human therapeutic antibodies for the treatment of infectious diseases.
Acumen is revolutionizing the diagnosis and treatment of autism and other disorders through smartphone-enabled digital behavior evaluation, improving outcomes for patients and simplifying care for specialists.
PhaseRx is developing a novel approach to intracellular delivery of macromolecules.
Inception 2 is focused on Oncology. The company is translating biological insights into novel, first-in-class small molecule drugs for CLL and other oncology indications spanning both liquid and solid tumors.
Inception 1 is translating biological insights into novel, first-in-class, small molecule drugs to treat diseases of aging.
RuiYi is a drug discovery and development company focused on first-in-class antibodies targeting G protein coupled receptors (GPCRs).
5AM Ventures is a seed-stage fund focused on creating and building biotech companies.